Hearing Loss, Noise-Induced
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Gateway BiotechnologyNC - Durham
2 programs2
Zonisamide 100Mg CapPhase 21 trial
Zonisamide 100Mg CapPhase 21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Gateway BiotechnologyZonisamide 100Mg Cap
Gateway BiotechnologyZonisamide 100Mg Cap
Clinical Trials (2)
Total enrollment: 27 patients across 2 trials
Noise-Induced Hearing Loss-Acute Exposure Treatment (UA)
Start: Nov 2021Est. completion: Dec 20223 patients
Phase 2Terminated
Noise-Induced Hearing Loss-Acute Exposure Treatment
Start: Oct 2021Est. completion: Sep 202324 patients
Phase 2Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.